

Date Mailed: September 30, 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Wuttke et al.
Serial No. Unassigned
Filed: September 30, 2003
For: AGENT FOR LOWERING PROLACTIN
Examiner: Unknown

Unit: --

CERTIFICATE OF EXPRESS MAILING		
<small>HEREBY CERTIFY THAT THIS PAPER OR FEE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE "EXPRESS MAIL POST OFFICE TO ADDRESSEE" SERVICE UNDER 37 CFR 1.10 ON THE DATE AND LABEL INDICATED BELOW AND IS ADDRESSED TO MAIL STOP PATENT APPLICATION, COMMISSIONER FOR PATENTS, P. O. BOX 1450, ALEXANDRIA, VA 22313-1450</small>		
<u>September 30, 2003</u>		<u>EV 305 241 505 US</u>
Date of Deposit and Signature	Ann Weiss	Express Label No.

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR § 1.98(d)**

Mail Stop PATENT APPLICATION
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313

Applicant's attorney submits herewith Form PTO-1449, "Information Disclosure Statement" by Applicant listing references of which he is aware, that he believes may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. § 1.56.

A copy of each of the disclosed patents and other references listed as other documents Nos. 1-18 is not being submitted herewith, because under Rule 37 C.F.R. § 1.98(d) this art was previously cited by the Examiner and/or the Applicant in connection with parent application U.S. Serial No. 09/856,219, filed September 24, 2001. This previously filed Application was cited by applicant in this present Application per 35 U.S.C. §§ 120 and 119.


Date Mailed: September 30, 2003

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability or that no other material information exists (37 C.F.R. 1.97(h)). Further the filing of this information disclosure statement shall not be construed as an admission against interest in any manner.

It is believed that this information disclosure statement is being filed before the mailing of a first office action on the merits. However, the Commissioner is hereby authorized to charge any fees required to Deposit Account No. 50-1597.

Respectfully submitted,

By:


Nisan A. Steinberg, Ph.D.
Registration No. 40,345

SIDLEY AUSTIN BROWN & WOOD
555 West Fifth Street
Los Angeles, California 90013-1010
Ofc: 213/ 896-6665
Fax: 213/896-6600

FORM PTO-1449 (Modified) List of Patents and Publications for Applicants Information Disclosure Statement	ATTY DOCKET NO. 20213-81002	SERIAL NO. Unassigned
	APPLICANT: Wuttke et al.	
	FILING DATE: September 30, 2003	GROUP ART UNIT —

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION YES	TRANSLATION No
	WO 96/24684	15.08.96					
	WO 99/63978	16.12.99					

OTHER ART (Including Author, title, Date, Pertinent Pages, Etc.)

1.	International Search Report, PCT/EP99/08507, International Filing Date 05/11/1999
2.	German Search Report, DE 198 53 476.0, 26 Mai 1999.
3.	XP-000913717, Sliutz, G. et al., <i>Agnus Castus Extracts Inhibit Prolactin Secretion of Rat Pituitary Cells, Hormone and Metabolic Research</i> , Vol. 25, pp. 253-255 (1993).
4.	XP-000913700, Milewicz, A. et al., (<i>Vitex agnus castus-Extrakt zur Behandlung von Regeltempoanomalien infolge latenter Hyperprolaktinämie, Ergebnisse einer randomisierten Plazebo-kontrollierten Doppelblindstudie (Vitex agnus castus extract in the treatment of luteal phase defects due to latent hyperprolactinaemia: Results of a randomized placebo-controlled double blind study)</i> , <i>Arzneimittel-Forschung</i> , Vol. 43, No. 7, pp. 752-756 (1993).
5.	XP-000913660 - Cahill, D. J. et al., <i>Multiple follicular development associated with herbal medicine</i> , <i>Human Reproduction</i> , Vol. 9, No. 8, pp. 1469-1470 (1994).
6.	XP-000913600- Ohsaki, Ayumi et al., <i>The Isolation and in vivo Potent Antitumor Activity of Clerodane Diterpenoid from the Oleoresin of the Brazilian Medicinal Plant, Copaifera Langsdorfii Desfon</i> , <i>Bioorganic & Medical Chemistry Letters</i> , Vol. 4, No. 24, pp. 2889-2892 (1994).
7.	XP-000913598, Chen, Zhen-Ping et al., <i>Studies on the Anti-Tumour, Anti-bacterial, and Wound-Healing Properties of Dragon's Blood</i> , <i>Planta Med.</i> , Vol. 60, pp. 541-545 (1994).

EXAMINER	DATE CONSIDERED;
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

List of Patents and Publications for Applicants Information Disclosure Statement	ATTY DOCKET NO. 20213-81002	SERIAL NO. Unassigned
	APPLICANT: Wuttke et al.	
	FILING DATE: September 30, 2003	GROUP ART UNIT -

OTHER ART (Including Author, title, Date, Pertinent Pages, Etc.)

8.	XP-000913597, Rojas, A. et al., <i>Smooth Muscle Relaxing Compounds from Dodonaea viscosa</i> , <u>Planta Medica</u> , Vol. 62, pp. 154-159 (1996).
9.	XP-000913581, Jarry, H. et al., <i>In vitro prolactin but not LH and FSH release is inhibited by compounds in extracts of Agnus castus: direct evidence for a dopaminergic principle by the dopamine receptor assay</i> , <u>Exp. Clin. Endocrinol.</u> , Vol. 102, pp. 448-454 (1994).
10.	XP-000907424, Han, Byung Hoon et al., <i>In Vitro Platelet Activating Factor Receptor Binding Inhibitory Activity of Pinusolid Derivatives: A Structure--Activity Study</i> , <u>J. Med. Chem.</u> , Vol. 41, pp. 2626-2630 (1998).
11.	XP-000907423, Males, Z. et al., <i>Composition of the essential oil of Vitex agunus-castus L. f. rosea fruits</i> , <u>Pharmazie</u> , Vol. 53, pp. 728-729 (1998)
12.	XP-000907422, Taguchi, Heihachiro, <i>Studies on the Constituents of Vitex cannabifolia</i> , <u>Chem. Pharm. Bull.</u> , Vol. 24, No. 7, pp. 1668-1670 (1976).
13.	Costa, Marta et al., <i>Assignment of ¹³C NMR data of methyl (+)-hardwickiate and its derivatives</i> , <u>IN: Magn. Reson. Chem.</u> , Vol 36, pp. 542-544 (1998), <u>Magn. Reson. Chem.</u> 36:542-544 (1998).
14.	McChesney, J. D. et al., <i>Ent-Clerodanes of Croton Sonderianus</i> , <u>In: Fitoerapia</u> , Bol. LXI, No. 1, pp. 172-175 (1990).
15.	XP-000907421, Kondo, Yoshikazu et al., <i>Studies on the Constituents of Vitex rotundifolia L. fil.</i> , <u>Chem. Pharm. Bull.</u> , Vol. 34, No. 11, pp. 4829-4832 (1986).
16.	Chemical Abstracts, Vol. 95, Ref. 115786q
17.	Rudi, A. et al., <i>Chelodane, Barekoxide, and Zaatirin—Three New Diterpenoids from the Marine Sponge Chelonaplysilla Erecta</i> , <u>J. of Natural Products</u> , Vol. 55, No. 10, pp. 1408-1414 (Oct 1992)
18.	Misra, R. et al., <i>Partial Synthesis of Kolavelool and Hardwickiic Acid</i> , <u>Tetrahedron Letters</u> , No. 22, pp. 2685-2686 (Mar 1968)

EXAMINER	DATE CONSIDERED;
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	